Nuclear Medicine Market 2023 World Study by Key Brands - Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma, Eli Lilly, SIEMENS, China Isotope & Radiation

Nuclear Medicine,or Radiopharmaceuticals, are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy) . Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

The global average price of Nuclear Medicine is in the decreasing trend, from 41.6 USD/Dose in 2011 to 39.5 USD/Dose in 2015. With the situation of global economy, prices will be in decreasing trend in the following five years.

The classification of Nuclear Medicine includes Tc-99, I-123/131, In-111, Xe-133, Th-201 and Ga-67, and the proportion of Tc-99 in 2015 is about 51.60%, and the proportion is stable from 2011 to 2015.
Nuclear Medicine is widely used in Diagnostic, Therapeutic. The most proportion of Nuclear Medicine is Diagnostic, and the market share in 2015 is 61.23%. The trend of Diagnostic is decreasing.

Over the next five years, projects that Nuclear Medicine will register a 7.6% CAGR in terms of revenue, reach US$ 6610 million by 2023, from US$ 4590 million in 2017.

This Latest Study on Nuclear Medicine Market Studies the Overall Market by Revenue (Value) and Market Share by Players, Profiles/Analysis, and Manufacturing Cost Analysis, Industrial Chain, Sourcing Strategy and Downstream Buyers, Marketing Strategy Analysis, Distributors/Traders, Market Effect Factors Analysis

Request a Free Sample Now at http://www.reportsweb.com/inquiry&RW00012073257/sample

This report studies the global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 players in each region, with sales, price, revenue and market share from 2013 to 2018, the top players:
GE Healthcare
Bracco Imaging
Mallinckrodt
Lantheus Medical Imaging
Bayer
Triad Isotopes
Nordion
Jubilant Pharma
Eli Lilly
SIEMENS
China Isotope & Radiation
Dongcheng

View Report Details at http://www.reportsweb.com/2018-top-5-nuclear-medicine-players-in-north-america-europe-asia-pacific-south-america-middle-east-and-africa

Main Points from RD

1 Nuclear Medicine Market Overview

2 Global Nuclear Medicine Sales, Revenue (Value) and Market Share by Players

3 Global Nuclear Medicine Sales, Revenue (Value) by Regions, Type and Application (2012-2017)

4 North America Top 5 Players Nuclear Medicine Sales, Revenue and Price

5 Europe Top 5 Players Nuclear Medicine Sales, Revenue and Price

6 Asia-Pacific Top 5 Players Nuclear Medicine Sales, Revenue and Price

7 South America Top 5 Players Nuclear Medicine Sales, Revenue and Price

8 Middle East & Africa Top 5 Players Nuclear Medicine Sales, Revenue and Price

9 Global Nuclear Medicine Players Profiles/Analysis

10 Global Nuclear Medicine Market Forecast (2017-2022)

11 Nuclear Medicine Manufacturing Cost Analysis

12 Industrial Chain, Sourcing Strategy and Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders

14 Market Effect Factors Analysis

15 Research Findings and Conclusion

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

505, 6th floor, Amanora Township,
Amanora Chambers, East Block,
Kharadi Road, Hadapsar, Pune-411028

This release was published on openPR.